Leqembi’s approval for Alzheimer’s treatment marks a turning point

The voices, values and lived experience of people living with dementia - and their families - must shape the path forward for Alzheimer's treatment 
Leqembi’s approval for Alzheimer’s treatment marks a turning point

On April 15, the agency approved Leqembi. File photo: Eisai Co Ltd via AP

THIS week marks a watershed moment as the European Commission approves Leqembi — the first drug authorised by the European Medicines Agency to slow progression of early-stage Alzheimer’s.

This landmark decision follows a protracted and controversial process, including an extraordinary escalation to an appeal committee. On April 15, the agency approved Leqembi just weeks after rejecting a similar drug, Kisunla, based on the benefit-risk profile. Both Leqembi and Kisunla are available in other regions such as Britain.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €120 €60

Best value

Monthly €10€5 / month

More in this section

Revoiced

Newsletter

Sign up to the best reads of the week from irishexaminer.com selected just for you.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited